Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Product information and disease descriptionProduct descriptionProduct information

Contraindications/Warnings/Precautions/Adverse effects

16 evidence topics · 10 sources

Warnings and precautions
FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

Adverse events of special interest: Launch-HTN
Hyperkalemia: Launch-HTN
Adverse events during 36 weeks of open-label treatment: Transform-HTN
EventLorundrostat (N=632), n (%)
Any serious adverse event“27 (4.3)”
Treatment-emergent adverse event leading to study drug withdrawal“37 (5.9)”
Hyperkalemia leading to study drug withdrawal“10 (1.6)”
Hyperkalemia requiring modification of trial drug“32 (5.1)”
Hyponatremia requiring modification of trial drug“28 (4.4)”
Hypotension with symptoms“13 (2.1)”
Serum potassium >6.0 mmol/L confirmed by repeat testing“16 (2.5)”
Decline in estimated glomerular filtration rate
Adrenal insufficiency and cortisol